Tay Therapeutics

Tay Therapeutics is a private, early-stage biotech based in London, advancing a portfolio of small molecule drug candidates. The company's strategy involves building its asset portfolio through internal discovery and strategic IP acquisitions, such as the BET inhibitor portfolio from Dundee University. Operating as a 'hub' for creating spin-outs, as evidenced by the launch of Hawkhill Therapeutics, Tay appears to be following a capital-efficient, asset-centric development model. Its focus on overcoming mutations suggests a platform targeting genetically defined diseases or resistance mechanisms.

Focus on small molecule discovery targeting epigenetic regulators and mutation-driven disease mechanisms, evidenced by BET inhibitor portfolio acquisition.

Competes with numerous biotech and pharmaceutical companies developing small molecule epigenetic modulators and targeted therapies for genetically defined diseases. Differentiation hinges on the ability to design molecules that effectively overcome specific resistance mutations.